SEER Logo

SEER Training Modules

Five-Year Survival Rates

Favorable Prognostic Factors for Malignant Lymphomas

Hodgkin Lymphoma Non-Hodgkin Lymphoma
Stage Early stage Early stage
Symptoms Asymptomatic Good performance score (Karnofsky)
Age at Dx Young Age < 60
Other Long remission 1 or fewer extranodal sites; normal LDH

Hodgkin Lymphoma (Adult)

Prognostic factors

Cell type (in order from most favorable to least favorable)—Lymphocyte predominant, Nodular sclerosis, Mixed cellularity, Lymphocyte depletion.

Presence or absence of "B" symptoms is an important prognostic indicator as are the presence of large masses, involvement of the spleen, and the absolute number of nodal sites of involvement.

Hodgkin lymphoma may be cured with chemotherapy, but the incidence of secondary acute nonlymphocytic leukemia within 10 years is more than 3%. The risk of subsequent solid tumor primaries is about 13% at 15 years.

Five year Disease Free Survival Rates

(from the National Cancer Institute's Physician Data Query System, July 2003)

Hodgkin Lymphoma Non-Hodgkin Lymphoma
Stage Early stage Early stage
Symptoms Asymptomatic Good performance score (Karnofsky)
Age at Dx Young Age < 60
Other Long remission 1 or fewer extranodal sites; normal LDH

Non-Hodgkin Lymphoma (Adult)

Prognostic factors
Stage Survival Rate
Stage I up to 90%
Stage II 78 - 90%
Stage IIIA 60 - 78%
Stage IIIB 50 - 60%
Stage IV 40 - 50%

Five Year Disease Free Survival Rates for Working Formulation Cell Types (all stages)

from Manual for Clinical Oncology, second edition, DA Casciato and BB Lowitz, Little Brown and Co., 1990)

Low Grade
A. Small lymphocytic 59%
B. Follicular small cleaved cell 70%
C. Follicular mixed 50%
Intermediate Grade
D. Follicular large cell 45%
E. Diffuse small cleaved cell 33%
F. Diffuse mixed small and large cell 38%
G. Diffuse large cell 35%
High Grade
H. Immunoblastic large cell 32%
I. Lymphoblastic 26%
J. Small noncleaved cell 23%